The Senate Appropriations Committee included funding for FDA’s Neurology Drug Program in its FY 2023 funding bill. Here is the language from its Explanatory Statement:
“The Committee provides $3,000,000 to support and enhance the neurology drug program. Unprecedented progress in understanding the cellular and molecular processes that underlie human nervous systems holds the promise of vast improvements in our ability to prevent neurological disease, diagnose it at an earlier stage, and treat it more effectively through targeted therapies. The Committee urges FDA to use this funding to develop policies and guidance that keep pace with scientific discovery in these areas, particularly as they apply to the prevention and early detection of neurological disease.